Related links

Nabarro advises GlaxoSmithKline on acquisition of Maxinutrition

16 December 2010

Nabarro is acting for GlaxoSmithKline (GSK) on the competition law side of its acquisition of Maxinutrition from Darwin Private Equity, which is subject to approval from the Office of Fair Trading. Maxinutrition is a UK company that manufactures protein-enhanced sports nutrition products. Subject to approval from the Office of Fair Trading, GSK will acquire 100 per cent of the shares of Maxinutrition, for a cash consideration of approximately £162 million including the repayment of outstanding debt.

Slaughter and May is advising GSK on corporate law aspects and Macfarlanes is acting for Darwin Private Equity on corporate and competition.

The Nabarro team is led by competition and GSK client partner Brian Sher, assisted by associate Ben Hockman. Commenting on the transaction, competition partner Brian Sher said:

"We are delighted to be advising GlaxoSmithKline on the competition aspects of this transaction which will give GSK a significant presence in the protein-based sports nutrition market".

If you have any queries please contact:

Brian Sher
Nabarro LLP
T +44 (0)20 7524 6453
b.sher@nabarro.com